ACIP voted to recommend MenB booster doses for people at ongoing increased risk of meningococcal serogroup B disease in June 2019 and the recommendation was published in 2020 (www.cdc.gov/mmwr/volumes/69/rr/pdfs/rr6909a1-H.pdf). As long as you use Bexsero (MenB-4C) as the booster dose, the patient does not need to restart the primary series. This patient should be given a booster dose of Bexsero now and receive subsequent booster doses every 2–3 years.
Brands of MenB vaccine work differently and are not interchangeable. The only time ACIP recommends restarting the primary series is if the brand used for the primary series is not known or is unavailable.